University of California, San Francisco.
Drug Industry Document Archive.

Resources
 
Articles
  • Hill K., et al. The ADVANTAGE Seeding Trial: A Review of Internal Documents. Annals of Internal Medicine 2008 Aug. 149(4):251-258. Available at: http://www.annals.org/cgi/content/full/149/4/251
    This paper cites 8 documents from Frederick Humeston v. Merck & Co and Brian Hermans v. Merck & Co.

  • Landefeld S, Steinman, M. The Neurontin Legacy - Marketing through Misinformation and Manipulation. The New England Journal of Medicine 2009 Jan 8;360(2):103-6. Available at: http://content.nejm.org/cgi/content/full/360/2/103
    This paper cites documents from Franklin vs. Parke-Davis, et al.

  • Ross J, et al. Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A case study of industry documents from Rofecoxib Litigation. JAMA. 2008;299(15):1800-1812. doi: 10.1001/jama.299.15.1800
    This paper cites 18 documents from Thomas Cona et. al. v. Merck & Co. that were added in March 2008.

  • Singer N. Medical papers by ghostwriters pushed therapy. The New York Times, August 4, 2009. http://www.nytimes.com/2009/08/05/health/research/05ghost.html?ref=research
    This article cites documents from Prempro Products Liability Litigation

  • Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: The promotion of gabapentin: An analysis of internal industry documents. Ann Intern Med. 2006 Aug 15;145(4):284-93. Available at: http://www.annals.org/cgi/content/full/145/4/284.
    This paper cites court documents from Franklin vs. Parke-Davis, et al.

  • Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero, LA. Characteristics and Impact of Drug Detailing for Gabapentin. PLoS Med. 2007 April; 4(4):e134. doi:10.1371/journal.pmed.0040134
    This paper cites documents from Franklin vs. Parke-Davis, et al.

  • Wilson D. Drug maker said to pay ghostwriters for journal articles. The New York Times, December 12, 2008. http://www.nytimes.com/2008/12/12/business/13wyeth.html?_r=1&scp=3&sq=duff%20wyeth&st=cse
    This article cites documents from Prempro Products Liability Litigation.

Further Resources
Franklin v. Parke-Davis and related claims were concluded in May 2004 with a $430 million settlement and an agreement to plead guilty to resolve civil liabilities and criminal charges pertaining to this case.
The U.S. Department of Justice press release for Franklin v. Parke-Davis is available at: http://www.usdoj.gov/opa/pr/2004/May/04_civ_322.htm
The PLoS Medicine Editors. Ghostwriting: The Dirty Little Secret of Medical Publishing That Just Got Bigger. 2009. PLoS Med 6(9): e1000156. doi:10.1371/journal.pmed.1000156
Waxman, HA. Memorandum to the Democratic Members of the Government Reform Committee: The marketing of Vioxx to physicians. May 5, 2005. Committee on Government Reform Minority Office, United States House of Representatives.
Available at: http://www.democrats.reform.house.gov/Documents/20050505114932-41272.pdf
Home     The Documents      The Project     Help      Resources     Privacy      Contact Us

  UCSF Library University of California, San Francisco ©2008 The Regents of the University of California